Actinium Pharmaceuticals (ATNM) said Tuesday it is launching a clinical program consisting of trials studying Actimab-A in combination with either Merck's (MRK) Keytruda or Bristol Myers Squibb's (BMY) Opdivo for the treatment of multiple solid tumors.
Actimab-A is meant to improve the efficacy of the immunotherapies by targeting myeloid derived suppressor cells, the company said.
The Actimab-A trials will include several controlled, head-to-head studies that will evaluate the combination of Actimab-A with Keytruda and Opdivo in comparison with the two drugs alone.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。